Tagged with R

CROs Riaz Bandali, President ESD of InVentiv Health Clinical discusses the ways in which the company’s unique combination of different technologies and capabilities will help lead the way to better healthcare and the ability to treat individuals more effectively. What was your initial mandate at InVentiv? Like many Canadian health and…

R&D Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has adapted to the changing needs of big pharma through risk mitigation. You founded Transition Therapeutics in 1998. What was the reasoning behind founding a biotech company focused on CNS…

medical tourism     The minister in charge of medical tourism in Taiwan speaks about the country’s advantages over its Asian neighbours, and how the new era of Taiwan’s medical services will make a difference for foreigners seeking medical treatment in the country.   Minister Wu, during our first interview with you…

Biosimilars Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars will be able to overcome the initial barriers, and where he sees EiGenix in the next several years. What has…

InterMune Michael Cloutier, President of InterMune, elaborates on the challenges of navigating the Canadian healthcare system as a small pharmaceutical company, and highlights some methods by which Canada can provide a stable environment for Canadian companies to grow. You have had an extensive and varied career, with positions in the Canadian…

R&D Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry to the global forefront.  Taiwan Supra Integration and Incubation Center (Si2C), was launched in November 2011 with the intention of…

Biosimilars Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent a bubble burst, and the crucial next steps in maintaining the momentum to continue growth within the industry. Please start…

Chang Gung Memorial Hospital Dr Yu-Ray Chen, Professor of Surgery at Chang Gung Memorial Hospital discusses the current state of Taiwan’s healthcare system, highlighting the fact that its current condition is unsustainable in the long run, and emphasizes the importance of international growth and collaboration for CGMH over the next five years.  Chang Gung…

Interface Biologics Tom Reeves of Interface Biologics (IBI) offers his input about the company’s roadmap towards commercialization, as well as IBI’s differentiation and the advantages of collaborating with international partners. You joined IBI in 2008, what was your initial mandate upon arriving here? My initial mandate was to demonstrate commercial viability. Since…

Investissement Québec Investissement Québec is a public corporation whose mission is to contribute to Québec’s economic development. Investissement Québec’s project manager, Stéphanie Murphy, discusses the role and contribution of pharmaceutical companies to Quebec’s economic landscape and the challenges associated with promoting Quebec as an attractive place for FDI. What are some of…

Charles River Charles River is the fifth largest CRO globally and the Canadian affiliate is the largest preclinical organization worldwide. Glenn Washer talks to us about the environment for contract research in Canada and the competitive advantages this offers the company in being able to provide a wide range of services. You…

Novartis Healthcare Thomas Weigold, President & Managing Director of Novartis Healthcare Philippines expounds upon the rapidly developing healthcare system in the Philippines, what is yet left to improve upon and how Novartis is aiming to change the way people think about their health and their lifestyles. Mr. Weigold, you started heading the…